The clinical success of Daromun, an intratumoral immunotherapy co-developed by Swiss biotech firm Philogen and evaluated under the direction of Professor Paolo Ascierto at the National Cancer Institute Pascale in Naples, represents a pivotal development in contemporary oncology. Designed as a neoadjuvant therapeutic strategy, Daromun is based on two fully human immunocytokines—L19IL2 and L19TNF—administered via … Leggi tutto Daromun and the Immunologic Rewriting of Melanoma Therapy: A Verifiable Global Assessment of Intratumoral Immunotherapy’s Emergence in Oncological Protocols